Artivion reports Q2 EPS 7c vs. 6c last year

Reports Q2 revenue $98.0M, consensus $97.66M. “In Q2, we continued to make substantial progress on our strategic growth initiatives to drive sustained and profitable growth, and we further solidified our position as the leader in the aortic disease space. Revenue growth in the second quarter was driven by year-over-year constant currency growth in On-X of 15% and stent grafts of 13%, both compared to Q2. We also saw continued revenue strength across Latin America and Asia Pacific, which grew 25% and 15%, respectively, in the second quarter on a constant currency basis compared to the same period last year. In addition to our strong revenue performance, adjusted EBITDA grew 35% this quarter, demonstrating our ability to scale the business and continue to expand adjusted EBITDA margins,” said CEO Pat Mackin. “Given our Q2 performance, we are raising our full year revenue and adjusted EBITDA expectations for 2024.”